Table 4.

Relation of diabetes status categories (normal glucose tolerance [NGT], pre-diabetes, type 2 diabetes [T2D]), and of glycemia ascertained as hemoglobin A1c (HbA1c), with brain amyloid standardized uptake value ratio (SUVR). Amyloid SUVR adjusted means and standard deviations (SD) are compared across T2D categories using analysis of covariance. Coefficients (β) and 95% confidence intervals (CI) relating HbA1c and amyloid SUVR were estimated using linear regression models. Model 1 is unadjusted; Model 2 is adjusted for age, sex, and APOE-ε4; Model 3 is adjusted for lipids, body mass index, and differences in medication (lipid, blood pressure, and diabetes).

		Model 1		Model 2		Model 3
	No.	mean (SD) or β (95% CI)	P value	mean (SD) or β (95% CI)	P value	mean (SD) or β (95% CI)	P value
Global Brain Amyloid SUVR
Type 2 diabetes categories
NGT	139	1.157 (0.011)		1.156 (0.011)		1.156 (0.013)
Pre-diabetes	100	1.180 (0.013)	0.19	1.182 (0.013)	0.13	1.177 (0.014)	0.21
T2D	111	1.146 (0.013)	0.53	1.145 (0.012)	0.47	1.150 (0.018)	0.82
P (global)			0.17		0.099		0.36
Hemoglobin A1c (HbA1c)
HbA1c	350	−0.10 (−0.20, 0.01)	0.074	−0.07 (−0.17, 0.03)	0.19	−0.05 (−0.18, 0.08)	0.46
Global Brain Amyloid SUVR below the positivity threshold
Type 2 diabetes categories
NGT	127	1.121 (0.005)		1.120 (0.005)		1.119 (0.006)
Pre-diabetes	90	1.136 (0.006)	0.075	1.137 (0.006)	0.030	1.133 (0.006)	0.073
T2D	105	1.126 (0.006)	0.59	1.127 (0.005)	0.32	1.131 (0.008)	0.32
P (global)			0.20		0.093		0.18
Hemoglobin A1c (HbA1c)
HbA1c	322	−0.01 (−0.06, 0.04)	0.68	0.004 (−0.04, 0.05)	0.86	0.01 (−0.05, 0.07)	0.80